The Business Development Office provides access to Queen Mary University of London cutting-edge capabilities and state-of–the-art facilities. Our team of Business Development Managers will identify relevant academic expertise to meet your commercial requirements through collaborative research, contract research and consultancy.
Quotient Sciences are dedicated to accelerating the development of new drugs for patients around the world. They provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via their Translational Pharmaceutics® platform.. . For more than 30 years, Quotient Sciences has brought innovation to early drug development programs for pharmaceutical companies worldwide. At the company’s purpose built facilities, real-time manufacturing of all types of dosage forms is co-located with its clinical pharmacology unit to maximise flexibility, speed and cost savings for clients.
With a client base representing companies from the FT Global 500 and FTSE listed companies, Reddie & Grose is recognised as a leading patent and trade mark firm. In 2009, the Managing Intellectual Property global patent survey ranked the firm as one of the UK’s top patent prosecution advisors. It consistently continues to achieve high rankings in all professional surveys.. . Reddie & Grose prides itself on delivering intellectual property protection for businesses in both the domestic and international marketplaces with a strong professional team of over 30 people from varied scientific backgrounds.. . The firm’s Cambridge office offers particular expertise in biotechnology, pharmaceutical, chemical, engineering, cleantech, instrumentation, medical device, materials, and software related inventions. Companies/academic institutions represented in this field by Reddie & Grose include: Diagnostics for the Real World, Haemostatix, Funxional Therapeutics, TCP Innovations, Trillion Genomics, Brax, Cambridge Biopolymers, Metalysis, University of Cambridge, Cambridge Broadband, i2, Cambridge Biotechnology Ltd and nCipher.. . Talk to us...
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation. Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer. Horizon offers a catalogue of over 1,000,000 cell and reagent products, which along with related research services, support a greater understanding of the function of genes across all species and the genetic drivers of disease, and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, and are used in the Company’s own R&D pipeline.. . Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”. https://www.horizondiscovery.com . . •
Riverlabs is a new and exciting 28-acre life sciences campus, ideally situated at the centre of the ‘Golden Triangle’ in Ware, Hertfordshire. 440,000 sq ft (GIA) will be available in three phases:
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com
No data available
Sagittarius IP is a firm of Chartered and European Patent Attorneys who specialise in chemical, pharmaceutical and biotechnology subject matter. We provide the following services: drafting, filing and prosecution of patent applications and representation before the UK and European Patent Offices, including oppositions and other contentious work; filing of international patent applications (PCT) and control of worldwide patent prosecution; advice on IP strategy; freedom to operate investigation; IP due diligence; and IP education. Sagittarius IP was set up in 2002 and opened a Cambridge office in 2009.
No data available
Scantox is a leading preclinical GLP-accredited CRO, specialized in providing services within the drug development process. The business is divided into the 4 divisions: Discovery, Genetic Toxicology, Regulatory Toxicology and Pharmaceutical Development & Analytical.
Based on decades of experience, Scantox is a trusted partner for CRO services for the pharmaceutical and medical devices industries. Services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Scantox Group is headquartered in Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund, Gothenburg and Solna). The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™.
Based on decades of experience, Scantox is a trusted partner for CRO services for the pharmaceutical and medical devices industries. Services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Scantox Group is headquartered in Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund, Gothenburg and Solna). The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™.
Scendea is an international product development & regulatory consulting Group, delivering market-leading scientific expertise & regulatory solutions, to advance healthcare innovation worldwide. We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs. Our expert team, based in the UK, the Netherlands, Australia, and the US, provide strategic and operational support in the fields of Non-Clinical, CMC, Clinical, and Regulatory to successfully guide products from early development to marketing approval.
Further information on our services can be seen on our website https://www.Scendea.com/services
Further information on our services can be seen on our website https://www.Scendea.com/services